The Hycolin range of antiviral products was developed and brought to key retail and professional markets at the beginning of the COVID-19 pandemic.
The antiviral performance of the Hycolin products, measured by laboratory experts independent to Mirius, allowed the product users to have confidence that the products were highly efficacious against the SARS-CoV-2 virus (the causative agent of COVID-19) and were therefore enhancing hygienic practice.
Since the beginning of the pandemic, the virus story has evolved, notably because of the emergence of variants (new forms) of the originally identified coronavirus, notably variants called Delta and Omicron. The question is, Do the Hycolin products work as effectively against variants of SARS-CoV-2 as against the original strain that was demonstrated months ago?
The answer is a simple – YES.
Variants of SARS-CoV-2 differ from each other in the arrangement of key molecules in the virus particle, but this altered shape does not interfere with the way the Hycolin antiviral products destroy the virus.
The so called ‘mode of action’ of the Hycolin products remains the same and the variant viruses offer no acquired resistance to being attacked, so the Hycolin products continue to offer highly effective antiviral properties and therefore they persist in contributing to enhanced hygienic practice.
DR Richard Hastings (Technical Director)
Available for Professional users and consumer home cleaning Hycolin is the must stock range as we continue to battle the current pandemic.
For more information about the Hycolin Professional range – Click Here
For more information about the Hycolin Retail range – Click Here
Dr Richard Hastings has a Phd in Microbiology with many years’ experience in biocides. He is highly skilled in REACH, BPR and registration issues for biocides on a global scale having develop new products and gained registration and acceptance of these products all over the world. He has established research and is a published author in antimicrobial technology.